Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Cardinal Tarcisio Bertone, the Vatican’s number two official and secretary of state, has called for universal, free access to HIV medications...
Neither HIV infection nor its treatment appears to be associated with hearing loss, reported Tuesday, July 19, at the 6th IAS Conference
Antiretroviral drug regimens containing Norvir (ritonavir)-boosted Reyataz appear to work just as well for women, compared with men, in...
Truvada reduced new infections among men who have sex with men and transgender women by more than 90 percent
The efficacy of Janssen Therapeutics’ Edurant (rilpivirine) is similar to that of Sustiva (efavirenz) over two years of treatment
Could people coinfected with HIV and hepatitis C virus benefit from Selzentry (maraviroc)? Possibly, according to an important new study
A new study shows that HIV-positive women are twice as likely to transmit the virus to a sexual partner if they use hormone-based birth contro...
Merck’s integrase inhibitor Isentress works as well as mainstay therapy efavirenz in HIV-positive individuals starting first time treatment
Encouraging preliminary results involving vaccine being developed by Maryland-based VIRxSYS Corporation were presented at 6th IAS Conference
Genital secretions from women living with HIV using antiretroviral therapy contain high drug concentrations and low amounts of virus
Drugs known to penetrate the central nervous system do not appear to offer protection against neuropsychological problems with HIV infection
Gilead’s experimental once-daily integrase inhibitor elvitegravir works as well as Merck’s approved INI Isentress in treatment
Giovanni Alemanno, published an open letter to Silvio Berlusconi, urging the country to allocate funds to Global Fund to Fight AIDS
Lersivirine, ViiV Healthcare’s experimental NNRTI, achieves similar rates of viral load suppression compared with Sustiva (efavirenz).
Starting antiretroviral therapy once a CD4 count falls below 550 was associated with 40% reduction in the risk of serious illness
ViiV Healthcare’s experimental integrase inhibitor dolutegravir was at least as effective as efavirenz (found in Sustiva and Atripla)
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.